title: CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy.
abstract: BACKGROUND
  Patients with advanced Hodgkin's disease failing to achieve complete remission with chemotherapy or developing disease progression within 1 year have a poor prognosis with salvage chemotherapy.
  
  
  METHODS
  Twenty-five patients fulfilling the above criteria after failing treatment with ChlVPP (chlorambucil, vinblastine, procarbazine and prednisolone) or its variant were treated with a new salvage regimen CAPE/PALE (cyclophosphamide, adriamycin, prednisolone, etoposide and lomustine), given for 6 courses at three weekly intervals.
  
  
  RESULTS
  Thirteen of the 25 patients (52%) achieved complete remission. After a minimum follow-up period of 38 months five of these patients remained free from disease progression. This regimen was very well tolerated.
  
  
  CONCLUSIONS
  CAPE/PALE produces results comparable to other salvage regimens in Hodgkin's disease. New strategies are however required for this patient group.
authors.affiliation: CRC Wessex Medical Oncology Unit, Royal South Hants Hospital, Brintons Terrace, Southampton, U.K.
authors.forename: A F
authors.initials: AF
authors.lastname: Fairey
authors.forename: G M
authors.initials: GM
authors.lastname: Mead
authors.forename: H W
authors.initials: HW
authors.lastname: Jones
authors.forename: J W
authors.initials: JW
authors.lastname: Sweetenham
authors.forename: J M
authors.initials: JM
authors.lastname: Whitehouse
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011239:Prednisolone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D016879:Salvage Therapy; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D002699:Chlorambucil; D011344:Procarbazine; D014747:Vinblastine; D005047:Etoposide; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone